CD34 and myocardial infarction: The authors performed a comprehensive search of several databases to identify preclinical and clinical studies using autologous CD34+ cell therapy for the treatment of CVD, including heart failures, such as dilated cardiomyopathy and ischemic cardiomyopathy, acute myocardial infarction (AMI), and refractory angina.